FDA

Updated daily, the FDA calendar gives you insight into FDA actions on companies and upcoming actions the FDA is expected to take. Benzinga's FDA calendar shows historical FDA data, upcoming dates that companies will be impacted by the FDA and ranges of dates.

Get Alert
CVM
CVMCEL-SCI Corp
Multikine
Head and Neck Cancer
—————11/20/2026
8:00 AM
Provided Update

CEL-SCI Corporation announced that its investigational cancer immunotherapy Multikine® (Leukocyte Interleukin, Injection) has been granted official designation under the Saudi Food and Drug Authority’s (SFDA) New Accelerator Program for Drugs in Rare Diseases (NADR).

View Source →
Get Alert
NCNA
NCNANuCana PLC
NUC-7738 (NuTide:701)
Solid tumors
—————11/20/2026
8:00 AM
Preclinical Data

NuCana plc announced new preclinical data showing that NUC-7738 enhanced the anti-cancer activity of carfilzomib, an approved proteasome inhibitor used to treat patients with multiple myeloma.

View Source →
Get Alert
BLTE
BLTEBelite Bio, Inc.
Tinlarebant
In Stargardt Disease
—————11/20/2026
8:00 AM
PDUFA Date

Belite Bio, Inc announced that the U.S. Food and Drug Administration (FDA) has informed the Company that (i) it has extended the review period for the New Drug Application (NDA) for tinlarebant for the treatment of Stargardt disease type 1 (STGD1) by three months, with the extended Prescription Drug User Fee Act (PDUFA) action date being May 12, 2027, and (ii) if no major deficiencies are identified during FDA’s ongoing review, the FDA plans to communicate proposed labeling requests and any anticipated postmarketing requirement requests, if necessary, with the Company by April 12, 2027.

View Source →
Get Alert
GILD
GILDGilead Sciences Inc
sacituzumab govitecan-hziy (SG)
Metastatic triple-negative breast cancer (TNBC)
Phase 3————11/20/2026
6:45 AM
Provided Update

Merck announced the pivotal Phase 3 TroFuse-015 trial evaluating sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate (ADC) licensed from Kelun-Biotech, met its primary endpoint of overall survival (OS) compared to treatment of physician’s choice (TPC, consisting of trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel) in the treatment of patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who have received two or more prior lines of systemic therapy.

View Source →
Get Alert
ERAS
ERASErasca, Inc
ERAS-0015
pan-RAS molecular glue
—————11/20/2026
7:00 AM
Updated data

Erasca, Inc. announced positive updated U.S. Phase 1 monotherapy and initial combination data reinforcing the best-in-class potential of pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors.

View Source →
Get Alert
UTHR
UTHRUnited Therapeutics Corp
UThymoKidney
in Patients with End-Stage Renal Disease
—————11/20/2026
7:00 AM
Provided Update

United Therapeutics Corporation announced thefirst clinical xenotransplant in its EXTEND study of the UThymoKidney™ in patients with ESRD.

View Source →
Get Alert

Recent FDA Approvals